Honz Pharmaceutical Co., Ltd. reported earnings results for the half year ended June 30, 2022. For the half year, the company reported sales was CNY 220.03 million compared to CNY 414.87 million a year ago. Revenue was CNY 229.13 million compared to CNY 423.55 million a year ago.

Net loss was CNY 87.77 million compared to CNY 57.64 million a year ago. Basic loss per share from continuing operations was CNY 0.195 compared to CNY 0.1281 a year ago. Diluted loss per share from continuing operations was CNY 0.195 compared to CNY 0.1281 a year ago.